Company intelligence / Profile preview
LB Pharmaceuticals
New York, New York, United Stateslbpharma.us ↗
- Ownership
- Public · LBRX
- Development stage
- Phase 2
01
Overview
LB-102 showed positive Phase 2 results in schizophrenia with statistically significant improvements in PANSS scores across all tested doses. The drug was generally safe and well-tolerated with common adverse events including insomnia, headache, anxiety, and agitation. The company plans to initiate Phase 3 trials in Q4 2025.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Financials
- Market cap
- $1.2B
- Total revenue
- $0
- Enterprise value
- $830.1M
Beyond the preview
Go deeper on LB Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LB Pharmaceuticals.